Key result
High Lp(a) linked to cardiovascular risk in women only when total cholesterol exceeds /dL.
Why the study?
Does the addition of Lipoprotein(a) to traditional risk factors improve cardiovascular risk prediction in women?
Cohort (n=36,092)
Yes
Does the addition of Lipoprotein(a) to traditional risk factors improve cardiovascular risk prediction in women?
Answers are grounded in this paper and cite their sources.
Lp(a) provides minimal improvement in cardiovascular risk prediction among women, with increased risk observed primarily in those with concurrent high total cholesterol.
Background While lipoprotein(a) [Lp(a)] is associated with incident cardiovascular disease (CVD), its contribution to prediction remains controversial. Objective We examined the association and clinical utility of Lp(a) with incident CVD in women. Methods A turbidimetric assay assessed Lp(a) in three cohorts of women [the Women’s Health Study (WHS, N=24,558), a case-cohort sample from the Women’s Health Initiative Observational Study (WHI, 1815 cases, subcohort =1989), and the Justification for Use of Statins in Prevention (JUPITER) trial (N=2,569)] and men from JUPITER (N=5,161). A WHS derivation sample (N=16,400) determined the form of association with incident CVD. This was tested in WHS validation data (N=8,158) and the other study samples. Models including traditional CV risk factors but with and without Lp(a) were compared using risk reclassification. Results In the WHS there was a curvilinear association, with increased CVD risk among those with Lp(a) above 50 mg/dL, but only among women with total cholesterol (TC) above 220 mg/dL. In the WHS test sample there was a small but significant change in the c-statistic (0.790 to 0.797, p=0.035) but no improvement in measures of reclassification. This pattern was replicated among women in the WHI and JUPITER. In contrast, there was a strong association of Lp(a) with CVD among men with low TC levels in JUPITER. Conclusion In three cohorts of women, Lp(a) was associated with CVD only among those with high TC, and improvement in prediction was minimal. These data have implications for Lp(a) in clinical practice among women and for trials of Lp(a)-lowering agents.
No takes yet. Share an insight, caveat, or question.
Cook et al. (2018) conducted a cohort in Incident cardiovascular disease (n=36,092). Lipoprotein(a) vs. Traditional cardiovascular risk factors without Lipoprotein(a) was evaluated on Incident cardiovascular disease prediction (c-statistic) (p=0.035). Lipoprotein(a) >/dL was associated with increased cardiovascular risk in women only when total cholesterol was >/dL, yielding a minimal change in the c-statistic.
Synapse has enriched 10 related papers. Consider them for comparative context: